It is in Phase 3 via Lilly's TRIUMPH programme, with one 2026 secondary estimate placing potential MHRA approval in late 2027 or 2028 [1][2] [unverified]
REM tends to show up more in the second half
Mechanisms of action and therapeutic application of gucagon-like peptide-1
18 UC is characterized by ulceration of the intestinal mucosal layer in the rectum and colon, which in turn affects the entire colon, resulting in dysregulation of intestinal immune factors and disruption of the structure and function of the intestinal barrier
[4] Understanding this pharmacological basis helps patients recognise that bloating, whilst uncomfortable, is a predictable consequence of how these medications work rather than an indication of treatment failure
This amino acid is the acetylated form of l-carnitine, providing an important energy supporting metabolite